ClinicalTrials.gg
CompletedNCT02256267Updated Jan 7, 2019Results posted

A Study of LY2835219 in Healthy Participants

A Phase 1 interventional study of LY2835219 and Rifampin in Healthy Volunteers, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2019-01-07.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The aim of this two-period study is to compare how much of the study drug gets into the blood stream when it is given as a single oral dose and when it is given as a single oral dose in combination with rifampin (a Food and Drug Administration [FDA] approved antibiotic that is used to treat tuberculosis, a bacterial infection that mainly affects the lungs, and other infections). Each participant will complete both study periods.

The study will last about 34 days. Screening is required within 28 days before study drug is given.

02

Conditions studied

  • Healthy Volunteers
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy sterile males or surgically sterile females or females
  • Have a (BMI) of 18 to 32 kilogram per meter square (kg/m\^2)

Exclusion criteria

Exclusion Criteria:

  • Have participated in a clinical trial involving product within the last 30 days
  • Have an abnormality in the 12-lead (ECG) that, in the opinion of the investigator, increases the risks associated with participating in the study
  • Have an abnormal blood pressure
  • Show evidence of (HIV), or
  • Have donated blood of more than 500 milliliters (mL) within the last month
  • Have used or intend to use over-the-counter or prescription medication including herbal medications within 7 days prior to dosing or during the study
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    LY2835219

    Single oral dose of LY2835219

    Drug: LY2835219

  • Experimental
    LY2835219 + Rifampin

    Single oral dose of LY2835219 with rifampin orally, once daily for 14 days

    Drug: LY2835219 · Drug: Rifampin

Interventions

  • Administered orally

    Also known as: abemaciclib

  • Administered orally

06

What researchers measure

Primary outcomes

  1. Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219

    Time frame: Period 1: Day 1- Predose,1, 2, 4, 6, 8, 10 hours, Days 2-9: 24, 48, 72, 96, 120, 144, 168, and 192 hours; Period 2: Day 7- Predose,1, 2, 4, 6, 8, 10 hours, Days 8-15: 24, 48, 72, 96, 120, 144, 168, 192 hours

  2. PK: Area Under the Concentration Time Curve AUC(0-∞) of LY2835219

    Time frame: Period 1: Day 1- Predose,1, 2, 4, 6, 8, 10 hours, Days 2-9: 24, 48, 72, 96, 120, 144, 168, and 192 hours; Period 2: Day 7- Predose,1, 2, 4, 6, 8, 10 hours, Days 8-15: 24, 48, 72, 96, 120, 144, 168, 192 hours

07

Results

Posted Aug 2, 2018

Participant flow

Period 1 (Day 1; Day 2 to Day 9 Washout)
Participant flow — Period 1 (Day 1; Day 2 to Day 9 Washout)
MilestoneLY2835219 Then LY2835219 + Rifampin
Started24
Received at least 1 dose of ly283521924
Completed23
Not completed1
Withdrew: Adverse event1
Period 2 (Day 1 to Day 6)
Participant flow — Period 2 (Day 1 to Day 6)
MilestoneLY2835219 Then LY2835219 + Rifampin
Started23
Received at least 1 dose of rifampin23
Completed23
Not completed0
Period 2 (Day 7 to Day 14)
Participant flow — Period 2 (Day 7 to Day 14)
MilestoneLY2835219 Then LY2835219 + Rifampin
Started23
Received ly2835219 + rifampin23
Completed22
Not completed1
Withdrew: Adverse event1

Outcome measures

PrimaryPharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219
Time frame:
Period 1: Day 1- Predose,1, 2, 4, 6, 8, 10 hours, Days 2-9: 24, 48, 72, 96, 120, 144, 168, and 192 hours; Period 2: Day 7- Predose,1, 2, 4, 6, 8, 10 hours, Days 8-15: 24, 48, 72, 96, 120, 144, 168, 192 hours
Reported as:
Geometric mean · nanogram per milliliter (ng/ml)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219
nanogram per milliliter (ng/ml)200 mg LY2835219200 mg LY2835219 + 600 mg Rifampin
Pharmacokinetics (PK): Maximum Concentration (Cmax) of LY2835219134 ± 4510.5 ± 58
Statistical analysis
  • 200 mg LY2835219 vs 200 mg LY2835219 + 600 mg Rifampin · Ratio of geometric least squares means: 0.0771 · 90% CI 0.0671 to 0.0886
PrimaryPK: Area Under the Concentration Time Curve AUC(0-∞) of LY2835219
Time frame:
Period 1: Day 1- Predose,1, 2, 4, 6, 8, 10 hours, Days 2-9: 24, 48, 72, 96, 120, 144, 168, and 192 hours; Period 2: Day 7- Predose,1, 2, 4, 6, 8, 10 hours, Days 8-15: 24, 48, 72, 96, 120, 144, 168, 192 hours
Reported as:
Geometric mean · nanogram x hour per mL (ng x h/mL)
PK: Area Under the Concentration Time Curve AUC(0-∞) of LY2835219
nanogram x hour per mL (ng x h/mL)200 mg LY2835219200 mg LY2835219 + 600 mg Rifampin
PK: Area Under the Concentration Time Curve AUC(0-∞) of LY28352194570 ± 53229 ± 48
Statistical analysis
  • 200 mg LY2835219 vs 200 mg LY2835219 + 600 mg Rifampin · Ratio of geometric least squares means: 0.0467 · 90% CI 0.0376 to 0.0581

Adverse events

Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LY2835219—0/24 (0%)8/24 (33.3%)
Rifampin—0/23 (0%)2/23 (8.7%)
LY2835219 + Rifampin—1/23 (4.3%)4/23 (17.4%)
Most frequent serious events
Most frequent serious events
EventLY2835219RifampinLY2835219 + Rifampin
SyncopeNervous system disorders0/240/231/23
Most frequent other events
Most frequent other events
EventLY2835219RifampinLY2835219 + Rifampin
NauseaGastrointestinal disorders1/241/233/23
Upper respiratory tract infectionInfections and infestations3/241/230/23
HeadacheNervous system disorders1/240/232/23
DiarrhoeaGastrointestinal disorders2/241/230/23
CoughRespiratory, thoracic and mediastinal disorders2/240/230/23

Baseline characteristics

Age, Continuous
Age, Continuous(years)LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin
Mean58.8 ± 7.4
Sex: Female, Male
Sex: Female, Male(Participants)LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin
Female21
Male3
Race (NIH/OMB)
Race (NIH/OMB)(Participants)LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American6
White15
More than one race3
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)LY2835219 Alone, Then Rifampin, Then LY2835219 + Rifampin
United States24
08

Study locations

1 site
  • For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.
    Dallas, Texas 75247, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2014, a primary completion of Nov 2014 and a completion of Nov 2014. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2018, 3 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 1, 2014
First posted
Oct 3, 2014
Start
Oct 2014
Primary completionActual
Nov 2014
CompletionActual
Nov 2014
Results first posted
Aug 2, 2018
Last update
Jan 7, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 7, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02256267
Responsible party
Sponsor
First posted
Oct 3, 2014
Start date
Oct 2014
Primary completion
Nov 2014
Completion
Nov 2014
Results posted
Aug 2, 2018
Last update
Jan 7, 2019

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Abemaciclib

Start the discussion